NEXGEL's Revenue Surge: A Growth Story You Can't Ignore!

Ladies and gentlemen, buckle up! We've got a growth story that's hotter than a summer day in Texas. NEXGEL, the hydrogel powerhouse, just reported its fourth quarter and full year 2024 financial results, and let me tell you, the numbers are off the charts! This is a company that's not just growing; it's exploding with growth, growth, growth!

First things first, let's talk about the elephant in the room: revenue. NEXGEL's fourth quarter 2024 revenue totaled a whopping $3.04 million, an increase of 181% compared to the same period the prior year. That's right, folks, 181%! And if you think that's impressive, wait until you hear about the full year 2024 revenue. It totaled $8.69 million, an increase of 112% compared to 2023. This is the third consecutive year that NEXGEL has achieved over 100% full year and fourth quarter revenue growth year-over-year. That's not just growth; that's a rocket ship to the moon!

Now, let's talk about the key drivers behind this incredible growth. NEXGEL has diversified its revenue streams across branded consumer products and contract manufacturing. The company's consumer products, including Medagel, Silly George®, Kenkoderm®, and Histasolv, in partnership with STADA, all performed exceptionally well. The acquisition of the international beauty brand Silly George and the partnership with STADA to launch Histasolv in North America have been significant contributors to revenue growth. Silly George's sales grew from an initial $2 million annual revenue run rate to over $5.0 million and growing. The partnership with STADA has also begun generating revenue, further bolstering NEXGEL's financial performance.

But that's not all, folks! NEXGEL's innovative product offerings, such as the SilverSeal® product line, have driven growth. The company made its first shipments of SilverSeal® to Cintas, which continues into the first quarter of 2025. This product line has been a key driver of revenue growth in the contract manufacturing segment.

And let's not forget about operational efficiency. NEXGEL's gross margin expanded from 9.2% in 2023 to 31.6% in 2024. That's a massive improvement, folks! This indicates that NEXGEL is effectively managing its costs and optimizing its operations to drive profitability. The company's forward guidance of $13 million in 2025 revenue and expectations to achieve positive EBITDA during the year suggest that the trend of gross margin expansion is likely to continue. This can drive future growth and profitability.



Now, you might be thinking, "This sounds too good to be true. What's the catch?" Well, let me tell you, there is no catch. NEXGEL is a company that's on fire, and it's only going to get hotter. The company's pipeline of potential new customers remains healthy and robust. NEXGEL expects to generate at least $13 million in revenue for 2025 and achieve positive EBITDA during the year. This forward guidance suggests that NEXGEL is well-positioned to continue its growth trajectory.

So, what are you waiting for? This is a no-brainer, folks! NEXGEL is a growth story that you can't ignore. The company's consistent year-over-year revenue growth of over 100% for the third consecutive year is a testament to its strategic focus on diversified revenue streams, successful acquisitions and partnerships, innovative product offerings, operational efficiency, and a strong pipeline of potential customers. These factors have contributed to NEXGEL's sustained performance and position it well for future growth.

Do this! Buy NEXGEL now and watch your portfolio soar to new heights! This is a growth story that you don't want to miss out on. So, buckle up and get ready for the ride of your life! NEXGEL is on fire, and it's only going to get hotter!